1. Measurable residual diseaase can be detected with multicolor cytometry or PCR-based methods.
2. Flow-MRD relies on the detection of leukemia-associated aberrant immunophenotype, while qPCR is a sensitive method for patients with specific gene mutations or translocations
3. Patients should get MRD assessment after 2 cycles of standard chemotherapy, (pre-transplant) and after the end of treatment in PB and BM (post-transplant).
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation